Marvel Biosciences Corp (TSE:MRVL)
TSXV:MRVL
Canadian Market

Marvel Biosciences Corp (MRVL) Income Statement

10 Followers

Marvel Biosciences Corp Income Statement

Last quarter (Q3 2024), Marvel Biosciences Corp's total revenue was C$―, a decrease of ― from the same quarter last year. In Q3, Marvel Biosciences Corp's net income was C$-307.31K. See Marvel Biosciences Corp’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jul 23Jul 22Jul 21Jul 20
Total Revenue
----C$ 0.00
Cost of Revenue
-C$ 887.52K-C$ 613.10KC$ 265.20K
Gross Profit
-C$ -887.52K-C$ -613.10KC$ -265.20K
Operating Expense
C$ 1.98MC$ 1.36MC$ 2.55MC$ 485.04KC$ 689.57K
Operating Income
C$ -1.98MC$ -2.37MC$ -2.55MC$ -1.10MC$ -954.77K
Net Non Operating Interest Income Expense
C$ -12.71KC$ -38.42KC$ -1.55KC$ 1.73KC$ -316.00
Other Income Expense
C$ -16.55KC$ -4.78K-C$ -1.94MC$ -570.00
Pretax Income
C$ -2.10MC$ -2.29MC$ -2.55MC$ -3.04MC$ -955.66K
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
C$ -2.10MC$ -2.29MC$ -2.55MC$ -3.04MC$ -955.66K
Basic EPS
C$ -0.06C$ -0.06C$ -0.08C$ -0.17C$ -0.03
Diluted EPS
C$ -0.06C$ -0.06C$ -0.08C$ -0.17C$ -0.03
Basic Average Shares
C$ 159.14MC$ 39.66MC$ 32.76MC$ 17.70MC$ 32.59M
Diluted Average Shares
C$ 159.14MC$ 39.66MC$ 32.76MC$ 17.70MC$ 32.59M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
C$ 1.98MC$ 2.25MC$ 2.55MC$ -1.10MC$ 954.77K
Net Income From Continuing And Discontinued Operation
C$ -2.10MC$ -2.29MC$ -2.55MC$ -3.04MC$ -955.66K
Normalized Income
C$ -1.82MC$ -1.68MC$ -1.88MC$ -3.04MC$ -955.09K
Interest Expense
-----
EBIT
C$ -2.05MC$ -2.26MC$ -2.55MC$ -3.04MC$ -954.77K
EBITDA
C$ -2.05MC$ -2.26MC$ -2.55M-C$ -954.36K
Currency in CAD

Marvel Biosciences Corp Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis